Abstracts tagged "SLE"

Abstract Number: 779 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis
Seyed-Foad Ahmadi¹, Golara Zahmatkesh², Masoud Majed³ and Sheetal Desai⁴, ¹Department of Medicine, University of California Irvine, Orange, CA, ²Department of Psychiatry, University of New Mexico, Albuquerque, NM, ³Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA
Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-analysis Background/Purpose: Current guidelines recommend that in suspected neuropsychiatric SLE (NPSLE), the initial diagnostic workup…
Abstract Number: 1666 • 2018 ACR/ARHP Annual Meeting
The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
Jennifer Rogers¹, Amanda M. Eudy², Lisa Criscione-Schreiber², David Pisetsky³, Kai Sun⁴, Jay Doss⁴ and Megan E. B. Clowse², ¹Medicine, Divison of Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Duke University, Durham, NC, ⁴Division of Rheumatology & Immunology, Duke University, Durham, NC
Background/Purpose: Patient-reported outcome measures (PROs) in SLE can capture patient specific information and the patient perspective, but clinical use can be challenging due to confounding…
Abstract Number: 2105 • 2018 ACR/ARHP Annual Meeting
Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes
Pooja KR, Brooklynne Thielen, Xavier Hernandez and Nathan Mortimer, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with various immunological abnormalities and a diverse range of clinical symptoms. In contrast to the…
Abstract Number: 2664 • 2018 ACR/ARHP Annual Meeting
Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus
Noortje Groot¹, Y.K. Onno Teng², Karina de Leeuw³, Marc Bijl⁴, Radboud J. E. M. Dolhain⁵, Els J. Zirkzee⁶, Ruth D.E. Fritsch-Stork⁷, Irene E.M. Bultink⁸ and Sylvia S.M. Kamphuis⁹, ¹Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Centre, Rotterdam, Netherlands, ²Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁴Internal Medicine and Rheumatology, Martini Hospital, Groningen, Netherlands, ⁵Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ⁶Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Childhood-onset SLE (cSLE) is a severe lifelong multisystem autoimmune disease. Long-term outcome data are limited. Here, we report for the first time on the…
Abstract Number: 395 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus (SLE) with Inflammatory Myositis
Nicole Bitencourt, Elizabeth (Blair) Solow and Bonnie L. Bermas, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study was to identify specific clinical features of patients with SLE who have inflammatory myositis. Methods: A retrospective chart review…
Abstract Number: 916 • 2018 ACR/ARHP Annual Meeting
Integrative Analysis of Multi-Omics Data in an Ethnically Diverse Lupus Cohort Identifies Distinct Molecular Subtypes of SLE
Cristina Lanata¹, Ishan Paranjpe², Joanne Nitiham³, Kimberly Taylor⁴, Brooke Rhead⁵, Milena Gianfrancesco⁶, Lisa Barcellos⁷, Louise Murphy⁸, Patricia Katz⁹, Laura Trupin⁶, Jinoos Yazdany², Maria Dall'Era², Marina Sirota¹⁰ and Lindsey A. Criswell⁹, ¹Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵University of California, Berkeley, Berkeley, CA, ⁶Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷School of Public Health, UC Berkeley, Berkeley, CA, ⁸Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease with heterogeneous disease manifestations and outcomes. We aimed to define how molecular differences underlie this…
Abstract Number: 1672 • 2018 ACR/ARHP Annual Meeting
Poor Sleep Quality Predicts Worsening SLE Disease Activity
Philip Chu¹, Alicia M. Hinze², Noor Al-Hammadi³, Lacey Feigl⁴, Nancy Mathis⁴, Deepali Sen⁵, Seth Eisen⁴, Yo-El Ju⁶ and Alfred Kim⁷, ¹Internal Medicine, Washington University School of Medicine, Saint Louis, MO, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, ⁴Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁵Rheumatology, Washington University School of Medicine, St. Louis, MO, ⁶Neurology, Washington University School of Medicine, Saint Louis, MO, ⁷Medicine/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Poor sleep quality is commonly observed in patients with SLE. We hypothesize that poor sleep contributes to worsening SLE. The aims of this study…
Abstract Number: 2107 • 2018 ACR/ARHP Annual Meeting
Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs
Nick Huang¹, Zhi-Wei Lai¹, Gourav Choudhary², Thomas Winans³, Ryan Kelly⁴, Katalin Banki⁵, Laurence Morel⁶ and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ³SUNY Upstate Medical University, Syracuse, NY, ⁴SUNY, Syracuse, NY, ⁵Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ⁶Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease that is characterized by the production of autoantibodies against nuclear antigens (ANA) and phospholipids…
Abstract Number: 2671 • 2018 ACR/ARHP Annual Meeting
Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
Laurence E Cheng¹, Hailing Hsu², Martin Kankam³, Nicholas Siebers⁴, Randall Stoltz⁵, Lubna Abuqayyas², Bella Ertik⁶, Barbara Sullivan², Lei Zhou² and Jane R Parnes², ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS, ⁴Covance, Madison, WI, ⁵Covance, Evansville, IN, ⁶Amgen Inc, Boston, MA
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. AMG 570 is a bispecific molecule targeting…
Abstract Number: 464 • 2018 ACR/ARHP Annual Meeting
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Grace Chiang^1,2, Sik Nin Wong³, Clara Law⁴, Kwok Piu Lee⁵, Cheuk Chun Szeto⁶, Chi Chiu Mok⁷, Lai-Shan Tam⁸ and Ting Fan Leung⁹, ¹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Paediatrics and Adolescent Medicine, Tune Mun Hospital, Hong Kong, Hong Kong, ⁴Medicine and Therapeutics, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong, ⁶Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Medicine and Geriatrics, Tune Mun Hospital, Hong Kong, Hong Kong, Hong Kong, ⁸Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong, ⁹Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Renal disease occurs in 50-70% of all childhood onset systemic lupus erythematosus (cSLE). The prevalence of LN is higher in children and the manifestations…
Abstract Number: 936 • 2018 ACR/ARHP Annual Meeting
Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
Takayuki Katsuyama¹, Hao Li¹, Denis Comte², Michael W. Mosho³, Andrew R. Gillooly³, George C Tsokos⁴ and Vaishali R. Moulton¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Rheumatology, Department of Medicine, Boston, MA, ³Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling and cytokine production, and aberrant numbers and/or function of regulatory T…
Abstract Number: 1681 • 2018 ACR/ARHP Annual Meeting
Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases
Chengappa KG¹, Gunjan Kumar², Swaminathan R P³ and Vir Singh Negi¹, ¹Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India, ²Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India, ³Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India
Background/Purpose: A new classification criteria for SLE was proposed at the ACR/ARHP 2017 annual meet. The aim of this study was to compare the performance…
Abstract Number: 2111 • 2018 ACR/ARHP Annual Meeting
Ifnβ Affects Osteogenesis-Adipogenesis Axis in SLE Bone Marrow
Lin Gao, Mary O'Connell, Jennifer Anolik and R. John Looney, Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: SLE patients are especially vulnerable to corticosteroid induced avascular necrosis. While it is appreciated that multiple factors contribute to AVN, the bone-fat axis in…
Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Jens Humrich¹, Caroline von Spee-Mayer², Philipp Enghard³, Angelika Rose⁴, Elise Siegert⁵, Tobias Alexander⁵, Falk Hiepe⁶, Gerd R. Burmester⁷ and Gabriela Riemekasten⁸, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Immunology, University Hospital Freiburg, Freiburg, Germany, ³Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁶Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 467 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry
Ohoud AlAhmed¹, Vidya Sivaraman², Melissa Moore-Clingenpeel³, Stacy P. Ardoin⁴ and Sharon Bout-Tabaku⁵, ¹Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Pediatrics, The Ohio State University, COLUMBUS, OH, ³Research, Nationwide Children's Hospital, Dublin, OH, ⁴Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁵Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: The co-occurrence of autoimmune disorders (AI) with systemic lupus erythematosus (SLE) in adults is associated with poor disease outcomes. We describe the co-occurrence of…

« Previous Page
1
…
5
6
7
8
9
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.